Pfizer to be biggest beneficiary of China pharma market, say Goldman Sachs analysts; firm also set for Japanese generics market

The world's largest drugmaker, USA-based Pfizer, is eyeing the Japanese generics market and, in an investment review of the company, Goldman Sachs said sales in emerging growth markets would become a significant factor in the company's revenues, a fact that it considers underappreciated by stock market investors. China is the major emerging market for Pfizer.

Reported by numerous news sources, Goldman expects emerging growth markets to produce $3.5 billion of revenue for Pfizer in 2012, of which $3 billion of will come from China.

In its annual business review for investment professionals held earlier this year, Pfizer said it wants to increase its share of China's biopharma market to 6% in 2012 from its present 4%.